Comparative Pharmacology
Head-to-head clinical analysis: QOLIANA versus TRAMADOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QOLIANA versus TRAMADOL.
QOLIANA vs Tramadol
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day. For moderate to severe pain, 50-100 mg IV or IM every 4-6 hours; maximum 600 mg/day.
None Documented
None Documented
Clinical Note
moderateTramadol + Torasemide
"The risk or severity of adverse effects can be increased when Tramadol is combined with Torasemide."
Clinical Note
moderateTramadol + Etacrynic acid
"The risk or severity of adverse effects can be increased when Tramadol is combined with Etacrynic acid."
Clinical Note
moderateTramadol + Furosemide
"The risk or severity of adverse effects can be increased when Tramadol is combined with Furosemide."
Clinical Note
moderateTramadol + Bumetanide
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Terminal elimination half-life: approximately 6.3 hours (range 5-9 hours) for tramadol; active metabolite M1 has half-life ~7-9 hours. Clinically, dosing interval is typically every 4-6 hours.
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Primarily renal (90%): ~30% as unchanged drug, ~60% as metabolites. Biliary/fecal: ~10%.
Category C
Category D/X
Opioid Agonist
Opioid Agonist
"The risk or severity of adverse effects can be increased when Tramadol is combined with Bumetanide."